Longmen Capital

Degron Therapeutics is a drug discovery platform focused on developing a new class of targeted protein degradation therapeutics, specifically small molecule molecular glue degrader drugs. The company aims to become a leader in the discovery and development of these innovative medicines, which target disease mechanisms that are often inaccessible to traditional small molecule inhibitors. By leveraging its advanced molecular glue protein degradation platform technology, Degron Therapeutics identifies and validates disease targets while creating novel selective compounds. This approach addresses significant unmet medical needs across various therapeutic areas. The company boasts a team of experienced executives and scientific leaders dedicated to enhancing treatment efficiency through its drug development initiatives.

Crystal Egg is a biopharmaceutical company dedicated to the independent research and development of first in class innovative new drugs for major diseases such as depression, chronic kidney disease, pain and rare diseases, as well as providing customers with high-quality products and R&D services in membrane protein-related fields. enterprise. The company has built membrane protein expression and purification platforms, structural biology platforms, pharmacology platforms and nanobody screening platforms, and has rich R&D pipelines in the fields of ion channels and GPCRs.

Innovo Therapeutics is a anti-cancer drug developer committed to research and creation of medications that target protein breakdown.

ICE Bioscience Inc. is a contract research organization based in Beijing, China, specializing in preclinical research solutions for electrophysiology and early drug discovery services. Founded in 2010, the company focuses on the development of ion channel-related pharmaceuticals, particularly targeting the neuronal and cardiovascular systems. ICE Bioscience offers a range of services, including ion channel profiling, cardiac safety panels, brain slice screening, and various molecular biology applications. The company has established proprietary ion channel cell lines for both voltage-gated and ligand-gated channels. Additionally, it maintains a diverse platform for target-based panel screening, supporting drug discovery across multiple therapeutic areas such as immunology, oncology, and CNS diseases. ICE Bioscience is committed to enhancing the drug discovery process through effective communication and flexible collaboration models, aiming to identify and validate drug targets and streamline the progression from compound screening to preclinical candidate selection.

Kaidi Medical is a developer of tumor immunotherapy drugs.

Crystal Egg is a biopharmaceutical company dedicated to the independent research and development of first in class innovative new drugs for major diseases such as depression, chronic kidney disease, pain and rare diseases, as well as providing customers with high-quality products and R&D services in membrane protein-related fields. enterprise. The company has built membrane protein expression and purification platforms, structural biology platforms, pharmacology platforms and nanobody screening platforms, and has rich R&D pipelines in the fields of ion channels and GPCRs.

QureBio focuses on the research and development of innovative macromolecular biopharmaceuticals. Its goal is to develop new therapeutic drugs for the treatment of refractory cancer, autoimmune diseases, and metabolic diseases in China and the world to benefit patients. QureBio has multiple technology platforms for antibody drug development including phage display technology platforms and hybridoma antibodies technology platform and monoclonal antibody platform. The company was founded in 2017 and is based in Pudong District, Shanghai.

Qi Xiangdong, founder of Qiyu Bio, said: “Innovation is the starting and future of Qiyu Bio, and it is the core driving force of enterprise development. Qiyu Bio will use the first-class antibody technology platform to build superior biopharmaceutical pipelines and explore the field of biotherapy. A big breakthrough. With the development and improvement of the company, Qiyu will have core competitiveness in more fields.

Beijing Zhongyin Technology Co., Ltd. is a professional enterprise engaged in the research and development of clinical genetic diagnosis, prevention and gene therapy for hereditary eye diseases. The company's clinical genetic diagnosis platform for hereditary eye diseases can provide fast, accurate, reliable and professional clinical genetic diagnosis services for hereditary ophthalmology patients.

Hopstem Biotechnology LLC is a Houston-based company that focuses on the development of neural stem cell technology and stem cell therapies specifically for neurological disorders. Established in 2019, the company specializes in the neural differentiation, cell banking, and cell engineering of human induced pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs). By leveraging its advanced technologies, Hopstem aims to enhance biomedical research and improve diagnostic and therapeutic options for various neurological conditions. Through its innovative approaches, the company seeks to provide effective treatment solutions for patients suffering from these disorders.

Beijing Zhongyin Technology Co., Ltd. is a professional enterprise engaged in the research and development of clinical genetic diagnosis, prevention and gene therapy for hereditary eye diseases. The company's clinical genetic diagnosis platform for hereditary eye diseases can provide fast, accurate, reliable and professional clinical genetic diagnosis services for hereditary ophthalmology patients.

Lyvgen Biopharma Co. Ltd., founded in 2016 and based in Shanghai, China, specializes in the research, development, and production of immuno-oncology drug candidates. The company focuses on creating innovative antibody therapies, including its proprietary PD-1 antibody SSI-361, which aims to activate specific receptors within the tumor microenvironment while minimizing immune-related side effects in healthy tissues. Additionally, Lyvgen offers services related to tumor immune agonistic antibodies, local activation strategies, and synthetic biology engineering, leveraging its cross-linking-dependent antibody platform to enhance therapeutic efficacy in cancer treatment.

Ractigen Therapeutics is an early-stage pharmaceutical company focused on developing first-in-class therapies that aim to selectively restore the expression of therapeutic genes silenced in diseased cells. Utilizing a groundbreaking technology known as RNA activation (RNAa), which originated from research at the University of California San Francisco, Ractigen is working on a diverse pipeline of candidate medicines targeting various conditions with significant unmet medical needs. The company’s innovative approach addresses diseases related to inadequate gene expression, concentrating on key therapeutic areas such as central nervous system disorders, tumors, liver diseases, and ophthalmic conditions. By leveraging its unique technology and a portfolio of innovative patents, Ractigen strives to deliver effective treatment options to patients.

Prosit Sole, established in April 2013 as Deyi Sunshine Biotechnology (Beijing) Co., Ltd., is a biotechnology company headquartered in Beijing's Zhongguancun Biomedical Park. The company focuses on the research and development of innovative biopharmaceuticals, particularly targeting rare and life-threatening diseases. Utilizing its specialized Sunshine Protein Optimization Platform, Prosit Sole has developed several groundbreaking drugs, including Pegelan for chronic norovirus infection, Sporphene for articular cartilage injury repair, and Perox for persistent gout. Each of these drugs is backed by independent intellectual property rights. The company is committed to advancing treatments for rare diseases while maintaining a mission to benefit humanity and improve public health. With plans for future growth, Prosit Sole aims to expand its therapeutic offerings and enhance its position as a leading biopharmaceutical innovator in China and beyond.

Sichuan Huanlong New Material Co., Ltd. specializes in the development and production of environmentally friendly bamboo fiber materials. With over two decades of experience, the company utilizes innovative bamboo fiber refining technology to expand the application of bamboo in various products, including tissue paper, paper towels, and toilet paper. By focusing on sustainable materials, Huanlong aims to enhance the value of the bamboo industry and promote ecological practices within the market. The company is committed to leading the green bamboo fiber material industry while ensuring that bamboo resources are fully recycled and utilized effectively.

Sirnaomics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapeutics for significant human diseases using RNA interference (RNAi) technology. Founded in 2007 and headquartered in Gaithersburg, Maryland, with additional offices in Cambridge, Massachusetts, and facilities in Suzhou and Guangzhou, China, Sirnaomics is dedicated to addressing critical medical needs in oncology, anti-fibrotic therapeutics, and viral infections. The company's product portfolio includes several small interfering RNA (siRNA) therapeutics such as STP705 for scar reduction, STP909 for colon cancer, and STP900 for HPV and cervical cancer, among others. Sirnaomics employs proprietary Polypeptide Nano-Particle (PNP) technology to enhance drug delivery, allowing effective targeting of the tumor microenvironment and various cell types, particularly in the liver. Through its innovative approach, Sirnaomics aims to create impactful treatments for diseases with large market opportunities.

KYEE is a manufacturer of products and services for the medical cloud business that covers many fields, such as medical cloud, smart ward, and big data in health care. The company's process of deepening medical information technology. KYEE helps medical institutions improve service quality and efficiency, ensuring medical safety effectively.

CF PharmTech, Inc. is a specialty pharmaceutical company based in Suzhou, China, focused on the development and manufacturing of inhalation products for the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. Founded in 2007, the company offers a range of products including metered dose inhalers, dry powder inhalers, nasal sprays, and nebulizers. In addition to its product offerings, CF PharmTech provides contract manufacturing organization (CMO) services and is actively involved in research and development in its specialized field. The company aims to provide high-quality and affordable medicines to enhance patient care and management of respiratory conditions, catering to a global market. Its headquarters are strategically located in the Caohu District, ensuring convenient transportation access to major cities like Shanghai and Beijing.

LeapMed is a manufacturer and supplier of ultrasound biopsy kits, specializing in medical devices designed for various applications, including abdominal, superficial, cardiac, endoscopic, and three-dimensional procedures. The company produces a range of disposable ultrasonic intervention consumables, which include precisely positioned ultrasonic puncture racks, biopsy needles, puncture needles, and nerve block needles. LeapMed emphasizes research and development in the field of medical ultrasound probes and puncture frames, aiming to enhance surgical precision and improve the efficiency of surgical operations.

SmartNuclide is focused on the discovery, manufacture, and marketing of nuclear medicine pharmaceuticals, specifically in the fields of diagnostics and therapeutics for cancer treatment. The company engages in research and development of radiopharmaceutical medications, including recombinant proteins and imaging agents. By concentrating on molecular nuclear oncology, SmartNuclide aims to provide innovative biological drug products that enhance the reliability and effectiveness of cancer therapies. Through its development pathways, the company seeks to contribute significantly to the biotechnology industry by offering advanced solutions for diagnosing and treating cancer.

SiBionics is a medtech company based in Shenzhen, China, focused on the research and development of active implantable medical devices and medical artificial intelligence. The company specializes in creating innovative solutions for various health conditions, including retinitis pigmentosa, diabetes, cardiovascular diseases, and gastrointestinal tumors. SiBionics develops artificial intelligence technologies for medical imaging and implantable devices, including retinal electrical stimulators and continuous glucose monitors. Their work also encompasses health management, disease screening, and diagnostics, using approaches such as visual coding, medical imaging AI, and big data analytics to enhance patient care and address chronic diseases. Through these advancements, SiBionics aims to provide cost-effective products that improve long-term monitoring and treatment options in the medical field.